Literature DB >> 29174431

Pediatric thyroid cancer patients referred to high-volume facilities have improved short-term outcomes.

Linda M Youngwirth1, Mohamed A Adam1, Samantha M Thomas1, Sanziana A Roman1, Julie A Sosa1, Randall P Scheri2.   

Abstract

BACKGROUND: Thyroid cancer is the most common endocrine malignancy in children, albeit still rare. This study sought to measure the association between outcomes and case volume of the treatment facility for pediatric patients with thyroid cancer.
METHODS: The National Cancer Data Base (1998-2011) was queried for all pediatric patients (age ≤ 18 years) with thyroid cancer. Demographic, clinical, and pathologic features were evaluated for all patients. Case volume of the treating facility was defined as the number of pediatric thyroid cancer patients at that facility during the study period. Restricted cubic spline modeling was used to determine a volume threshold associated with decreased risk of 30-day readmission. Patients were assigned to volume groups based on this threshold. Logistic regression was utilized to estimate the effect of volume on 30-day readmission.
RESULTS: In total, 4,466 patients met inclusion criteria. The majority were girls (79.1%), white (86.1%), and underwent total thyroidectomy (86.9%). Compared with patients treated at the low-volume facilities, those treated at the high-volume facilities were more likely to have medullary thyroid cancer (10.7% versus 3.7%) and undergo total thyroidectomy (90.8% versus 86.3%) (all P < .01). After adjustment, treatment at low-volume facilities was associated with an increased likelihood of readmission after operative treatment (odds ratio = 3.52, P = .01).
CONCLUSION: Pediatric patients with thyroid cancer treated at low-volume facilities are more likely to be readmitted after thyroid surgery than patients treated at high-volume facilities. Providers should consider the case volume status at the treating facility when referring these children for thyroid surgery.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 29174431     DOI: 10.1016/j.surg.2017.09.042

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  3 in total

1.  Improved outcomes for papillary thyroid microcarcinoma care: active surveillance and case volume.

Authors:  Francesco Freni; Bruno Galletti; Francesco Galletti; Gianlorenzo Dionigi
Journal:  Ther Adv Endocrinol Metab       Date:  2018-05-04       Impact factor: 3.565

2.  Replication of newly proposed TNM staging system for medullary thyroid carcinoma: a nationwide study.

Authors:  Jes Sloth Mathiesen; Jens Peter Kroustrup; Peter Vestergaard; Per Løgstrup Poulsen; Åse Krogh Rasmussen; Ulla Feldt-Rasmussen; Sten Schytte; Stefano Christian Londero; Henrik Baymler Pedersen; Christoffer Holst Hahn; Jens Bentzen; Sören Möller; Mette Gaustadnes; Maria Rossing; Finn Cilius Nielsen; Kim Brixen; Christian Godballe
Journal:  Endocr Connect       Date:  2019-01-01       Impact factor: 3.335

3.  Optimal surgeon and hospital volume thresholds to reduce mortality and length of stay for CABG.

Authors:  Ying-Yi Chou; Juey-Jen Hwang; Yu-Chi Tung
Journal:  PLoS One       Date:  2021-04-14       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.